About Us Dev
About Us
Who We Are
Glyvantis Bio is a biotechnology company and University College Dublin spin-out developing precision glycoengineering technologies for biologics.
The company combines expertise in antibody development, CHO cell biology, metabolic modelling and biologics manufacturing with a deep understanding of the importance of consistent glycan profiles for improved therapeutic function, stability and manufacturability across therapeutic antibody drug development.
Key Potential Benefits of Glyvantis Bio Technology
Enables consistently high galactosylation across monoclonal antibody production systems
Supports improved control of glycan profiles in CHO-based biologics manufacturing
Reduces variability associated with antibody glycosylation during development and scale-up
Creates opportunities for differentiated follow-on biologics prior to loss of exclusivity
Enables enhancement strategies for clinically validated antibody scaffolds
Expands design flexibility for next-generation antibody formats, including bispecifics and ADCs